Moore MJ - Search Results

1

Prostate specific antigen response to mitoxantrone and prednisone in patients with refractory prostate cancer: prognostic factors and generalizability of a multicenter trial to clinical practice.

Dowling AJ, Czaykowski PM, Krahn MD, Moore MJ, Tannock IF. Dowling AJ, et al. Among authors: moore mj. J Urol. 2000 May;163(5):1481-5. J Urol. 2000. PMID: 10751862

2

How American oncologists treat breast cancer: an assessment of the influence of clinical trials.

Belanger D, Moore M, Tannock I. Belanger D, et al. J Clin Oncol. 1991 Jan;9(1):7-16. doi: 10.1200/JCO.1991.9.1.7. J Clin Oncol. 1991. PMID: 1985172

3

Are treatment strategies of urologic oncologists influenced by the opinions of their colleagues?

Moore MJ, O'Sullivan B, Tannock IF. Moore MJ, et al. Br J Cancer. 1990 Dec;62(6):988-91. doi: 10.1038/bjc.1990.422. Br J Cancer. 1990. PMID: 2257231 Free PMC article.

4

How expert physicians would wish to be treated if they had genitourinary cancer.

Moore MJ, O'Sullivan B, Tannock IF. Moore MJ, et al. J Clin Oncol. 1988 Nov;6(11):1736-45. doi: 10.1200/JCO.1988.6.11.1736. J Clin Oncol. 1988. PMID: 3054004 Clinical Trial.

5

Quality assessment of clinical trials in bladder cancer.

Tannock I, Moore M. Tannock I, et al. Eur Urol. 1988;14 Suppl 1:46. doi: 10.1159/000473045. Eur Urol. 1988. PMID: 3181246 No abstract available.

6

Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer.

Moore MJ, Osoba D, Murphy K, Tannock IF, Armitage A, Findlay B, Coppin C, Neville A, Venner P, Wilson J. Moore MJ, et al. J Clin Oncol. 1994 Apr;12(4):689-94. doi: 10.1200/JCO.1994.12.4.689. J Clin Oncol. 1994. PMID: 7512127 Clinical Trial.

7

A phase II study of methotrexate, vinblastine, doxorubicin and cisplatin plus recombinant human granulocyte-macrophage colony stimulating factors in patients with advanced transitional cell carcinoma.

Moore MJ, Iscoe N, Tannock IF. Moore MJ, et al. J Urol. 1993 Oct;150(4):1131-4. doi: 10.1016/s0022-5347(17)35706-3. J Urol. 1993. PMID: 8371371 Clinical Trial.

8

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, Murphy KC. Tannock IF, et al. Among authors: moore mj. J Clin Oncol. 1996 Jun;14(6):1756-64. doi: 10.1200/JCO.1996.14.6.1756. J Clin Oncol. 1996. PMID: 8656243 Clinical Trial.

9

Supportive care is not the only option in prostate cancer patients resistant to hormone therapy: the argument against.

Jewett MA, Khakpour G, Moore MJ. Jewett MA, et al. Among authors: moore mj. Eur Urol. 1996;29 Suppl 2:45-8. doi: 10.1159/000473839. Eur Urol. 1996. PMID: 8717463 Review.

10

Overview of Canadian trials in hormonally resistant prostate cancer.

Moore MJ, Tannock IF. Moore MJ, et al. Semin Oncol. 1996 Dec;23(6 Suppl 14):15-9. Semin Oncol. 1996. PMID: 8996579 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

797 results

Search Page